Abstract 3958
Background
Digestive Cancers Europe (DiCE), a European digestive cancer patients umbrella organization, planned and executed a cross-sectional survey in 15 European countries on the Unmet Needs of Patients Living with mCRC to examine the challenges and needs and QoL of those living with mCRC.
Methods
DiCE partner organisations, together with clinicians and nurses recruited patients for the survey (paper-based and online). The survey included demographics, data on discovery of the disease, diagnosis and treatment and the EORTC QLQ-C30 and CR29. Single data entry from the paper surveys was done by DiCE. Descriptive statistics and regression analyses were run to examine the global QoL score, function (F) - and symptom-specific scores, the item on financial difficulties and CR29 scores and their association with patient and disease characteristics and care setting by country and overall.
Results
883 surveys from Austria, Belgium, Cyprus (CY), Germany, Hungary (HU), Italy, Netherlands (NL), Norway, Serbia (RS), Poland, Spain (SP), UK, Portugal, Turkey and Ireland were collected. Only 8 countries with samples over 35 were analyzed on their own. Completion rates across QoL items were high (91-94%). Large variation across countries have been observed in mean scores (Table). Eastern vs Western Europe contrasted sharply, with Serbia and Poland reporting lower functional and much higher symptom scores for fatigue, nausea, vomiting, pain and insomnia. Regression analyses indicated that after adjustment for age, gender and care setting country differences remained significant. Patterns in results across dimensions of EORTC QLQ-CR29 were similar.Table:
659P
Mean (SD) | Global QoL | Physical F | Role F | Emotional F | Cognitive F | Social F |
---|---|---|---|---|---|---|
Lowest score | 55.94 (21.10) RS | 69.06 (23.93) CY | 62.58 (34.73) CY | 53.51 (28.35) RS | 71.31 (24.6) RS | 54.04 (25.91) RS |
Highest score | 69.26 (20.68) HU | 84.29 (17.87) SP | 81.76 (25.41) SP | 80.92 (21.04) NL | 87.86 (19.13) HU | 80.91 (24.63) HU |
OVERALL | 62.02 (21.75) | 74.25 (20.85) | 71.41 (28.76) | 68.25 (26.41) | 78.58 (23.39) | 68.56 (28.99) |
Conclusions
Country specific mean QoL scores in all function/symptom dimensions varied greatly across countries. This study indicates that care setting and other country-specific circumstances have important associations to QoL. Real-world mCRC patients’ QoL may be lower than those recruited in clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
EuropaColon / Digestive Cancers Europe.
Funding
Merck, BMS, Sandoz and Sirtex.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5694 - Findings from a new specialist remote Counselling Service for Neuroendocrine Neoplasm (NEN) patients and family members
Presenter: Catherine Bouvier
Session: Poster Display session 2
Resources:
Abstract
4725 - Hematologic malignancies in temozolomide-treated metastatic pancreatic neuroendocrine tumors
Presenter: Nicole Balmaceda
Session: Poster Display session 2
Resources:
Abstract
5842 - Efficacy and toxicity of combination chemotherapy with cyclophosphamide, vincristine and an anthracycline in patients with metastatic extrapulmonary neuroendocrine carcinoma
Presenter: Leonidas Apostolidis
Session: Poster Display session 2
Resources:
Abstract
1543 - An Australian multi-centre experience of the use of peptide receptor radionuclide therapy for bronchial carcinoid tumours.
Presenter: Lisi Lim
Session: Poster Display session 2
Resources:
Abstract
4175 - Extra-pulmonary (EP) high grade (HG) neuroendocrine carcinoma (NEC): real-life outcomes of fifty-eight patients from a Portuguese cancer center.
Presenter: Rita Conde
Session: Poster Display session 2
Resources:
Abstract
3274 - Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNET)
Presenter: Shira Sherman
Session: Poster Display session 2
Resources:
Abstract
3534 - HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
Presenter: Milton Barros
Session: Poster Display session 2
Resources:
Abstract
2137 - Clinical utility of Metabolic Tumor Volume in Papillary Thyroid Carcinoma
Presenter: Norihiko Takemoto
Session: Poster Display session 2
Resources:
Abstract
3864 - Correlation of thyroglobulin (Tg) oscillations with progression-free survival (PFS) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid carcinoma (DTC) treated with multikinase inhibitors (MKI).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract
2820 - Analytical validation of a thyroid cancer diagnostic method based on the relative quantification of CLDN10, HMGA2 and LAMB3 expression
Presenter: Mateus Barrosfilho
Session: Poster Display session 2
Resources:
Abstract